- Accelerated fourth quarter sales growth to 13.5%
- Fourth quarter gross margin expanded 310 bps and adjusted gross margin* expanded 230 bps
- Fourth quarter cash from operations of $19.3 million increased 86.3%
- Provides full-year 2025 financial guidance reflecting continued above market revenue growth and continued operating margin expansion
DURHAM, N.C., March 11, 2025 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced fourth quarter and full-year financial results for the year ended December 31, 2024, and provided its financial guidance for full-year 2025.
“Our Bioventus team delivered strong results in the fourth quarter to conclude a very successful and transformational year for our company,” said Rob Claypoole, Bioventus President and Chief Executive Officer. “Looking forward, we believe we are well positioned to build on this positive momentum, driving above-market revenue growth with a multitude of diverse growth drivers, while enhancing profitability and accelerating cash flow to create significant shareholder value.”
Fourth Quarter 2024 Financial Results
For the fourth quarter, worldwide revenue totaled $153.6 million, an increase of 13.5% compared to the prior year, driven by double-digit growth in Pain Treatments and Surgical Solutions.
Net loss from continuing operations was $0.3 million, compared to net loss from continuing operations of $7.7 million in the prior-year period. Adjusted EBITDA* from continuing operations of $28.3 million advanced 28.3% from $22.0 million last year due to strong revenue growth and adjusted gross margin expansion.
There was no loss per share of Class A common stock from continuing operations compared to a loss of $0.10 per share last year. Non-GAAP earnings per share from continuing operations* was $0.15 per share, compared to income of $0.07 per share in the prior year.
Full-Year 2024 Financial Results
Bioventus’ full-year 2024 worldwide revenue totaled $573.3 million, an increase of 11.9% compared to the prior year. On an organic* basis, revenue increased 14.4%, driven by double-digit growth in Pain Treatments and Surgical Solutions.
Full-year 2024 net loss from continuing operations was $43.8 million, compared to net loss from continuing operations of $121.2 million in the prior year. Adjusted EBITDA from continuing operations* of $108.9 million advanced 22.5% from $88.9 million last year due to strong revenue growth and adjusted gross margin expansion.
Loss per share of Class A common stock from continuing operations was $0.52 per share, compared to a loss of $1.54 per share last year. Non-GAAP earnings per share from continuing operations* was $0.49 per share, compared to $0.02 per share in the prior year.
